CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (loss)	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2022		412,385
Beginning balance at Dec. 31, 2022	$ 1,040,609	$ 4,124	$ 2,106,886	$ (1,064,230)	$ (5,560)	$ (611)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	15,959			16,022		(63)
Other comprehensive income (loss)	2,011				2,011
Exercise of stock options (in shares)		2,002
Exercise of stock options	9,617	$ 20	9,597
Vesting of restricted stock units (in shares)		79
Vesting of restricted stock units	0	$ 1	(1)
Shares withheld related to net share settlement (in shares)		(1)
Shares withheld related to net share settlement	(28)		(28)
Stock-based compensation expense	13,672		13,672
Ending balance, (in shares) at Mar. 31, 2023		414,465
Ending balance at Mar. 31, 2023	$ 1,081,840	$ 4,145	2,130,126	(1,048,208)	(3,549)	(674)
Beginning balance (in shares) at Dec. 31, 2023	406,387	406,387
Beginning balance at Dec. 31, 2023	$ 661,021	$ 4,064	1,986,899	(1,326,826)	(2,298)	(818)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(6,034)			(6,064)		30
Other comprehensive income (loss)	(449)				(449)
Exercise of stock options (in shares)		1,434
Exercise of stock options	2,455	$ 14	2,441
Vesting of restricted stock units (in shares)		1,170
Vesting of restricted stock units	0	$ 11	(11)
Shares withheld related to net share settlement (in shares)		(122)
Shares withheld related to net share settlement	(646)	$ (1)	(645)
Issuance of common stock (in shares)		1,974
Issuance of common stock	15,230	$ 20	15,210
Stock-based compensation expense	$ 16,909		16,909
Ending balance, (in shares) at Mar. 31, 2024	410,843	410,843
Ending balance at Mar. 31, 2024	$ 688,486	$ 4,108	$ 2,020,803	$ (1,332,890)	$ (2,747)	$ (788)